AFLIBERCEPT (EYLEA HD) prior authorization at UnitedHealthcare
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
The PA criteria you'll need to meet
UnitedHealthcare reviews AFLIBERCEPT (EYLEA HD) prior authorizations against its medical policy for Vascular Endothelial Growth Factor Inhibitor [EPC]. The FDA-approved indication (2023) is INJECTABLE. UnitedHealthcare-specific context: UHC's parent UnitedHealth Group owns Optum (PBM Optum Rx) and Surest. Surest plans have different cost-sharing rules. State complaints flow to state insurance department + DOL/EBSA for self-funded.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in Vascular Endothelial Growth Factor Inhibitor [EPC]
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- UnitedHealthcare's medical policy URL referenced in the cover letter
UnitedHealthcare's common denial patterns
Pre-empting these patterns in the initial submission cuts rework and shortens time-to-approval:
- GLP-1 weight-loss exclusion
- Out-of-network reduction citing UCR
- Step therapy on biologics
- Prior auth denied for advanced imaging
- Quantity limits on specialty drugs
If the PA is denied
UnitedHealthcare gives prescribers and members 180 days to file an internal appeal. Standard appeal decisions return within 30 days. Submit through the provider portal (https://www.uhcprovider.com) with the same packet plus a peer-reviewed citation supporting AFLIBERCEPT (EYLEA HD)for the patient's indication.
Contact UnitedHealthcare
- Provider portal: https://www.uhcprovider.com
Frequently asked questions
What documentation does UnitedHealthcare need for AFLIBERCEPT (EYLEA HD) prior auth?
UnitedHealthcare's typical PA packet for AFLIBERCEPT (EYLEA HD): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For Vascular Endothelial Growth Factor Inhibitor [EPC], expect clinical-criteria documentation specific to this class.
What's the turnaround time at UnitedHealthcare?
Standard AFLIBERCEPT (EYLEA HD) PA decisions at UnitedHealthcare: 30 days. Urgent / expedited (member's life or function at risk): 72 hours under 45 CFR §147.136.
What does UnitedHealthcare most often reject AFLIBERCEPT (EYLEA HD) for?
Across UnitedHealthcare's book the common rejection patterns include: GLP-1 weight-loss exclusion; Out-of-network reduction citing UCR; Step therapy on biologics. For AFLIBERCEPT (EYLEA HD) specifically, expect step-therapy challenges and indication-restriction reviews when the use is at the edge of the FDA label or off-label.
How do I prep for a peer-to-peer with UnitedHealthcare on AFLIBERCEPT (EYLEA HD)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Generate the AFLIBERCEPT (EYLEA HD) PA packet
Open ApprovalHelp — generate a AFLIBERCEPT (EYLEA HD) prior-auth packet tailored to UnitedHealthcare's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com